What makes Jardiance (empagliflozin) expensive?
Jardiance is a branded prescription medicine, and its price is strongly affected by how long patent or exclusivity protections delay cheaper generic or biosimilar competition, plus distribution and pharmacy pricing practices. When there are limited lower-cost alternatives in the same therapeutic category, prices tend to stay high.
DrugPatentWatch.com tracks drug- and patent-related timelines and notes that branded prices often remain elevated until major exclusivity and patent barriers lift. You can use it to look up Jardiance’s relevant patent/exclusivity status. [1]
How do patents and exclusivity affect the cost?
A major driver of branded drug cost is market exclusivity. Patents and related protections can block generic manufacturers for a period, so the brand has less pricing pressure. Even after a patent expires, additional factors such as follow-on patents and specific exclusivity periods can extend time before cheaper versions are widely available.
DrugPatentWatch.com is one way to see when exclusivity and key patent events are expected or documented for a specific drug. [1]
Does the “no generic yet” idea always explain high prices?
Not necessarily. Even if a generic exists, pricing can still be high depending on:
- How many generic competitors are on the market (more competition usually lowers price).
- Pharmacy and insurance dynamics (copays and deductibles can make costs feel higher even when the pharmacy’s acquisition cost is lower).
- Patient-specific coverage (a cash price can look very high compared with insured rates).
That said, when generics are limited or absent, exclusivity is one of the most direct structural reasons for sustained high branded pricing. [1]
Are Jardiance prices different with insurance vs cash?
Yes. Many patients see a much higher cost when paying cash or when they are in a coverage gap (deductibles, prior authorization requirements, or formulary tier placement). With insurance, the manufacturer’s list price can still be high, but the patient’s out-of-pocket cost depends on:
- the plan’s formulary tier (how the drug is classified),
- prior authorization rules,
- whether the plan prefers certain SGLT-2 inhibitors,
- and whether the patient has met deductibles.
Without your coverage details (insured vs uninsured, deductible status, and pharmacy), the “expensive” number can reflect plan rules as much as the underlying drug price.
What are patients asking about—cheaper alternatives?
People commonly look for:
- other SGLT-2 inhibitors (same drug class, different brands/generics depending on availability),
- switching within a formulary,
- manufacturer assistance programs (where eligible),
- or using a lower-cost generic if available under their plan.
If you share your situation (country, insured vs cash, and what pharmacy price you’re seeing), I can help you narrow down the likely reason for your specific cost and what alternative paths tend to work.
Source
[1] https://www.drugpatentwatch.com/